FindDrugs.org

WellMedr Weight Loss / GLP-1 Review

Weight Loss / GLP-1 · Reviewed Sep 21, 2026

5.17/10
WellMedr operator trust5.76/10See the full WellMedr brand review
Cash-pay

Our verdict

WellMedr is unusually open about the parts of compounded GLP-1 telehealth that are normally hidden — it names the medical group that prescribes, names the pharmacy that fills, and sets out to the day when a refund stops being available. It is unusually closed about the part that is normally published: the price. No core GLP-1 treatment on the site carries a figure, and the only way to learn what a plan costs is to start the intake and reach checkout.

Price

from $199/mo · 8 plans

Visit WellMedr

We may earn a commission if you sign up through this link. It never affects rankings or scores. Not medical advice.

Key takeaways

  • Names both its clinical network and its fulfilment pharmacy — most of this category names neither
  • No price is published for any core GLP-1 treatment before checkout
  • Payment is taken before WellMedr’s own clinical review, and refunded in full automatically if treatment is declined
  • The 21-day plan is not monthly and can bill up to eighteen times in a year
  • A detailed safety page sits alongside a tolerability claim for the microdose line that the brand elsewhere says is unstudied

What is WellMedr Weight Loss / GLP-1?

WellMedr is a cash-pay telehealth service operated by Wellmedr LLC of St. Petersburg, Florida. For weight management it sells compounded semaglutide and compounded tirzepatide as weekly injections or once-daily dissolving tablets, a line of low-dose blends that combine those molecules with vitamins, and month-to-month plans for branded Zepbound and Ozempic. Clinical care is delivered by the OpenLoop Health provider network and prescriptions are filled by Mycelium Pharmacy.

Treatment options

Prices as of Sep 21, 2026 — verify current on the brand's site.

Getting started with WellMedr

  1. Complete the online intake questionnaire on the WellMedr site
  2. Pay at checkout — this happens before WellMedr’s clinical review
  3. A clinician in WellMedr’s OpenLoop network then assesses the intake and decides whether treatment is appropriate
  4. If treatment is declined, the full initial payment is refunded automatically within seven business days
  5. If approved, the prescription is filled and shipped in unbranded packaging, typically arriving within a week

Methodology scorecard

Scored on Sep 21, 2026 under methodology v6

5.17/10
  • Legitimacy & Accreditation
    Critical

    Evidence (as scored Sep 21, 2026): The operating entity is named with a street address and phone number, the clinical network and the fulfilment pharmacy are both named, and WellMedr publishes the weight-loss disclosure Florida statute requires. No third-party accreditation is claimed anywhere on the site and none was verified. The FDA enforcement register returns no entry. — FDA warning-letter register — search for "wellmedr", Sep 21, 2026

  • Clinical Oversight & Safety
    Critical

    Evidence (as scored Sep 21, 2026): WellMedr routes every intake to a licensed clinician for assessment and states plainly that a prescription is never guaranteed. It publishes a dedicated GLP-1 safety page carrying the boxed warning, the medullary thyroid carcinoma and MEN 2 contraindications, pregnancy guidance and the tirzepatide interaction with oral contraceptives. No individual clinician and no medical director is named, and the care coach is a Certified Medical Assistant rather than a clinician. — dailymed.nlm.nih.gov, Sep 21, 2026

  • Sourcing Transparency & Legal Context
    High

    Evidence (as scored Sep 21, 2026): Mycelium Pharmacy — our U.S.-licensed fulfillment pharmacy — Wellmedr — Privacy Policy 1, Sep 21, 2026

  • Data Privacy & Security
    Medium

    Evidence (as scored Sep 21, 2026): WellMedr publishes a full HIPAA Notice of Privacy Practices naming the covered entities and both partners, and a CCPA notice that states it does not sell personal information, excludes health data and prescription details from cross-context behavioural advertising, and honours Global Privacy Control. No cookie-consent mechanism is served on the condition-specific pages, which do load third-party analytics and advertising tags. — WellMedr (wellmedr.com), Sep 21, 2026

  • Pricing Transparency & Value
    Critical

    Evidence (as scored Sep 21, 2026): "title":"Default Title","price":"0.00" — Wellmedr — Injectable Semaglutide.Json, Sep 21, 2026

  • Policy Clarity & Fairness
    High

    Evidence (as scored Sep 21, 2026): The refund and cancellation policy is the most specific in this corpus: a full automatic refund within seven business days if the clinician declines, a precisely defined cut-off for when a refund stops being available, no charge for a different or higher-priced plan without affirmative acceptance, and a rule that a later confirmation cannot increase the price. It also discloses that the 21-day plan is not monthly and can bill up to eighteen times in a year. The Terms contradict it on the consultation fee. — WellMedr (wellmedr.com), Sep 21, 2026

  • Access & Speed
    Medium

    Evidence (as scored Sep 21, 2026): Orders ship within one to two business days of provider approval with three to five day delivery, shipping is free and packaging unbranded, and WellMedr says its service is available in all fifty states. — WellMedr (wellmedr.com), Sep 21, 2026

  • Transparency & Disclosure
    Critical

    Evidence (as scored Sep 21, 2026): The compounded-medication disclosure is explicit and repeated, and WellMedr discloses that its published results come from comparable brands rather than its own studies. Semaglutide and tirzepatide are approved by the FDA in named branded products and the compounded versions are not among them. WellMedr’s general FAQ nonetheless tells readers the opposite. Against that, the microdose page markets the low-dose line on an expectation of tolerability for most members while also saying those formulations have not been studied, and the Terms and the Refund Policy give different answers on whether the consultation fee is refundable. — Drugs@FDA approval record — application 215256, Sep 21, 2026

  • Support & Care Model
    Supporting

    Evidence (as scored Sep 21, 2026): Unlimited provider messaging is included, every GLP-1 patient is assigned a care coach at no extra charge, and the brand publishes a phone number, two email addresses and a contact form. — WellMedr (wellmedr.com), Sep 21, 2026

  • Titration Autonomy
    High

    Evidence (as scored Sep 21, 2026): Tailored dosage adjustments based on your individual response — dailymed.nlm.nih.gov, Sep 21, 2026

  • Weight-Management Care Model
    Medium

    Evidence (as scored Sep 21, 2026): WellMedr LLC provides technology and non-clinical administrative support. WellMedr does not practice medicine, prescribe medication, or manufacture, compound, or dispense medication. — Wellmedr — Weight Loss Consumer Bill Of Rights, Sep 21, 2026

  • Eligibility Screening
    High

    Evidence (as scored Sep 21, 2026): Payment is collected at checkout before clinical review. Payment does not guarantee approval, a prescription, a particular medication, dose, or treatment result. — Wellmedr — Refund And Cancellation Policy 1, Sep 21, 2026

Pricing & cancellation

Visit WellMedr

All-in price

from $199/mo · 8 options

Cost structure
Subscription. 21-day, 3-, 6- and 12-month plans; the 21-day plan is not monthly and can bill up to 18 times a year.
Insurance vs. cash
Cash-pay
Deal structure
Cancellation
Cancel any time from the dashboard; cancellation stops future renewals and does not reverse a processed payment. Full automatic refund within seven business days if the clinician declines treatment.
Forced subscription
Required

Pros & cons

Pros

  • Names both its clinical network (OpenLoop Health) and its fulfilment pharmacy (Mycelium Pharmacy) — most of this category names neither
  • Refund rules are unusually specific: a full automatic refund within seven business days if the clinician declines treatment, and no charge for a different or higher-priced plan without the patient accepting it first
  • Publishes a dedicated GLP-1 safety page carrying the boxed warning, the thyroid and pancreatitis contraindications and the tirzepatide interaction with oral contraceptives
  • States plainly and repeatedly that compounded semaglutide and tirzepatide are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality
  • Publishes the Florida Weight-Loss Consumer Bill of Rights required by state statute, naming the operating entity and its street address

Cons

  • No price is published for any core GLP-1 treatment before checkout — every product variant reads $0.00 on the site
  • Payment is taken at checkout before WellMedr’s clinical review decides whether treatment is appropriate
  • The compounded products are not FDA-approved on its own safety page and footer, yet its general FAQ tells readers the opposite
  • The microdose pages market the low-dose line on an expectation of tolerability for most members, on the same page that says those formulations have not been studied
  • The Terms say consultation fees are non-refundable once intake is submitted; the Refund Policy says the full initial payment is refunded automatically if the clinician declines
  • Only an 18-or-over rule is published; the BMI and clinical criteria are applied inside the intake, after payment
  • No third-party accreditation is claimed anywhere on the site, and none was verified

Safety

Talk to a licensed clinician

WellMedr publishes a dedicated GLP-1 safety page, and it is one of the more complete in this category. It carries the boxed warning for thyroid C-cell tumours that the approved labels for these molecules bear, the medullary thyroid carcinoma and MEN 2 contraindications, guidance to stop treatment in pregnancy, and the interaction in which tirzepatide may reduce the effectiveness of oral hormonal contraceptives. It lists pancreatitis, gallbladder and kidney warning signs and gives the Poison Control number. Set against that, the microdose pages market the low-dose line on an expectation of tolerability for most members, while the same page states that those formulations have not been studied for specific health outcomes.

Common side effects

  • Nausea, vomiting, diarrhoea and constipation are the common gastrointestinal effects described for this drug class
  • Severe, persistent abdominal pain that may spread to the back can indicate pancreatitis — WellMedr tells patients to stop and contact a clinician immediately
  • Upper abdominal pain, fever, yellowing of the skin or eyes, or clay-coloured stools can indicate a gallbladder problem
  • Persistent vomiting or diarrhoea can cause severe dehydration and kidney problems
  • WellMedr gives the Poison Control number, 1-800-222-1222, for a suspected overdose or dosing error

Who should not take it

  • A personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2
  • A previous serious allergic reaction to semaglutide, tirzepatide or an ingredient in the prescribed formulation
  • Existing problems of the pancreas, gallbladder, kidneys, stomach or intestines, including severe gastroparesis
  • Pregnancy, planned pregnancy or breastfeeding — WellMedr states semaglutide should be stopped at least two months before a planned pregnancy
  • Use of another GLP-1, diabetes or weight-management medication, or of insulin or a sulfonylurea

The bottom line

WellMedr suits someone who has already decided on compounded GLP-1 treatment, wants to know who prescribes it and who fills it, and is willing to enter an intake before learning the price. Anyone who wants a price before a card goes in, or a published eligibility threshold before paying, should look elsewhere in this category.

Visit WellMedr

We may earn a commission if you sign up through this link. It never affects rankings or scores. Not medical advice.

See how WellMedr ranks among GLP-1 providers

Frequently asked questions

How much does WellMedr cost?

WellMedr does not publish a price for its core GLP-1 treatments. Every product variant on the storefront is listed at zero and the figure is reached only inside the intake and checkout. Two of the combination microdose products show $199 a month.

Is WellMedr’s medication FDA approved?

The compounded semaglutide and compounded tirzepatide WellMedr sells are not FDA-approved, and its safety page says so directly. WellMedr also sells branded Zepbound and Ozempic, which are FDA-approved. One page of its general FAQ tells readers the opposite, which the rest of the site contradicts.

Who prescribes and who fills the prescription?

Clinical care is provided by OpenLoop Health, a licensed medical group and provider network, and the privacy notice names Mycelium Pharmacy as the fulfilment pharmacy. No individual clinician is named.

Can I get a refund?

If the clinician declines treatment, the full initial payment is refunded automatically within seven business days. After that, refunds depend on whether the pharmacy has begun preparing the prescription. The Terms and Conditions state that consultation fees are non-refundable once intake is submitted, which is not what the refund policy says.

Do I need a BMI above a certain number?

WellMedr restricts treatment to adults aged 18 or over. Beyond that it publishes no BMI threshold and no clinical criterion — those are applied inside the intake, after payment.

Work at WellMedr?

If something here is wrong or out of date, send us a correction request. We read every one and decide what changes — it does not edit the review or move a score.

Sources & how we researched this

Scored on 12 of 14 factors · 15 sources cited

Brand site

Regulatory

What we couldn't verify

  • No price is published. Each of the four core GLP-1 products returns a single storefront variant priced at zero and the page copy carries no figure. The price appears only inside the intake and at checkout, and reaching it means driving the questionnaire in a rendered browser — which we do not do on a host whose terms refuse automated access. The two $199 figures we do cite are on combination microdose products, not the core treatments.
  • The minimum age is published (18 or over); the BMI threshold and the clinical criteria are not, on any page we read. They are applied inside the intake by the clinical network, and the same rendering restriction applies as for price.
  • The fulfilment pharmacy is named but its regulatory category is not stated anywhere on the site, and we did not attempt to verify the pharmacy’s licence.
  • The state corporate registry returned HTTP 403 to our retrieval. We hold no terms reading for that host, so under default-deny we did not render it. The registration is unverified — not absent.
  • The federal-docket check ran on 2026-09-21 against the CourtListener REST API v4 (the only sanctioned route — courtlistener.com is refused on terms), with the positive control "Mochi Health" returning 15 records, so a zero result from this run is a measurement and not a failed search. It found one entry naming WellMedr as a party: KOLMIND, LTD. v. WELLMEDR, LLC, District of New Jersey, removed to federal court on 2026-09-10 (Notice of Removal; subject of the underlying complaint not yet available). WHAT THIS DOES NOT ESTABLISH: the retrievable record carries the caption, the court and the filing date and nothing more — nature of suit and cause are both empty — so the subject of the case, its merits and whether it concerns patients, medicine or a commercial dispute are all unknown. No score reflects it, because scoring a filing whose subject we could not read would be inventing the part we could not read. Separately, WellMedr's clinician network OpenLoop Healthcare Partners PC is named as a party in 4 records, including Burley v. OpenLoop Healthcare Partners, PC (D. Nev., 2025-07-16); those concern the network, not WellMedr.
  • The review platform that carries the volume refuses automated access in its terms, and we do not render a host that refuses us. A figure surfaced by a search engine is not a reading of the page, so none is cited.
  • The fifty-state claim is the brand’s own and its FAQ states a narrower position. We did not verify it against state licence records.
  • Neither figure carries a source on the page. The brand states elsewhere that its published results reflect comparable telehealth brands rather than its own studies, and that the microdose formulations have not been studied for specific health outcomes. Recorded as unsourced brand claims; FindDrugs neither repeats them as fact nor disputes them.
Last reviewed Sep 21, 2026 · methodology v6View the ledger

Top pick

WellMedr 5.17/10